Mebendazole Prevents Meningioma Invasion in 3D Patient-Derived Spheroids (2026)
In a 2026 preclinical study using patient-derived 3D spheroids, mebendazole prevented cellular invasion in 89% of meningioma samples by disrupting Rho-GTPase-mediated microtubule function. This is early laboratory evidence, not a clinical trial.
By Sanare Lab · August 8, 2026 · 5 min read
Key Takeaway
A 2026 preclinical study using patient-derived 3D spheroids showed that mebendazole prevented cellular invasion in 89% of meningioma samples by disrupting Rho-GTPase (Ras homolog family guanosine triphosphatase) signaling and altering cytoskeletal dynamics. Meningioma is the most common primary brain tumor, and grade II tumors invade brain tissue, which is linked to recurrence and poor prognosis. This is laboratory evidence only, not a human clinical trial, and the drug is not approved for cancer therapy.
Brain tumors known as meningiomas arise from the meninges, the protective membranes surrounding the brain and spinal cord. While many meningiomas are low-grade (grade I) and slow-growing, grade II meningiomas can invade adjacent brain tissue, a feature that strongly predicts recurrence and worse outcomes. Standard treatment includes surgery and radiation, but recurrent or invasive cases remain challenging.
Drug repurposing the search for new uses among existing, well-characterized medications has gained attention in oncology. Mebendazole, an antiparasitic (anthelmintic) drug that inhibits microtubule formation, has shown anticancer activity in preclinical models of glioblastoma, medulloblastoma, and other cancers. Now, a 2026 study in Oncology Research evaluates whether mebendazole can block the invasive behavior of meningioma cells using a 3D culture model.
Table of Contents
- What Is Meningioma and Why Invasion Matters
- Study Design: 3D Patient-Derived Spheroids
- What the Study Found
- Mechanism: Rho-GTPase and Microtubules
- Limitations and Evidence Level
- Frequently Asked Questions
What Is Meningioma and Why Invasion Matters
Meningioma accounts for approximately 37% of all primary brain tumors, making it the most common type. Most are grade I (benign) and treated with observation or surgery. However, grade II (atypical) meningiomas show invasive behavior, which is a diagnostic criterion and a major risk factor for recurrence after surgery. Invasion into surrounding brain tissue makes complete removal difficult and correlates with poorer long-term survival.
Currently, there are no approved drugs that specifically target meningioma invasion. Temozolomide chemotherapy is used in some cases, but its efficacy is limited. This gap has motivated researchers to explore repurposed drugs with known safety profiles and blood-brain barrier penetration.
Study Design: 3D Patient-Derived Spheroids
The study, published in Oncology Research in 2026, used primary patient-derived meningioma cell lines rather than generic cell lines. Cells were cultured as 3D spheroids and embedded in an extracellular matrix-like gel to mimic the tumor microenvironment. This model captures cell-to-cell interactions and invasion dynamics better than flat 2D cultures.
Both grade I and grade II meningioma samples were tested. The spheroids were divided into two groups: one treated with mebendazole and one untreated control. The researchers then assessed whether the cells could invade the surrounding matrix using microscopy and mass spectrometry-based proteomics to identify molecular changes.
What the Study Found
The results were striking in the 3D model:
- Untreated controls: 9 of 10 grade I spheroids and 10 of 12 grade II spheroids showed active invasion into the surrounding matrix.
- Mebendazole-treated: Invasion was prevented in 89% of samples (8 of 9 grade I; 9 of 10 grade II).
This represents a near-complete blockade of invasive behavior in a patient-derived model. Mass spectrometry proteomics also revealed differences in protein expression between grades and between male and female samples within each grade, suggesting that biological sex may influence drug response at the molecular level.
Mechanism: Rho-GTPase and Microtubules
Mebendazole is a benzimidazole anthelmintic that binds to beta-tubulin, a structural protein in microtubules. In parasites, this blocks cell division. In cancer cells, it can disrupt the microtubule network that tumors use for migration and invasion.
The proteomics data in this study pointed to the Rho-GTPase signaling pathway as the key target. Rho GTPases (guanosine triphosphatases) are molecular switches that regulate the cytoskeleton the internal scaffolding of cells. By disrupting this pathway, mebendazole altered cytoskeletal dynamics, preventing the physical rearrangements cells need to invade tissue.
Importantly, the effect was observed in both male and female patient-derived spheroids, suggesting the mechanism is broadly applicable across sexes.
Limitations and Evidence Level
This study is preclinical it was conducted entirely in 3D cell culture, not in animals or humans. While 3D spheroids are more realistic than 2D cultures, they do not replicate the full immune system, blood supply, or drug metabolism of a living organism. Key caveats include:
- No animal model or human clinical data was included.
- Drug concentration and dosing regimen in the culture may not translate directly to patients.
- Long-term effects, resistance development, and combination with standard therapy are unknown.
The study itself notes that "more research is needed." However, the authors highlight mebendazole's high tolerability, known safety profile, low cost, and blood-brain barrier penetration as reasons it could be a good candidate for further investigation in meningioma.
For background, see our guide to how fenbendazole compares with mebendazole.
We cover this in more depth in our article on fenbendazole in brain cancer and glioblastoma.
You can map out a weight-based schedule using our dosage calculator.
Frequently Asked Questions
What is mebendazole and why is it being studied for cancer?
Mebendazole is an antiparasitic (anthelmintic) drug that blocks microtubule formation in parasites. Researchers have observed that it also inhibits cancer cell proliferation, migration, and invasion in laboratory models. It is not approved for cancer treatment, but its low cost, known safety profile, and ability to cross the blood-brain barrier make it an attractive candidate for drug repurposing research.
What is a 3D spheroid model and why is it better than a flat culture?
A 3D spheroid is a ball-shaped cluster of cells that mimics the three-dimensional architecture of a real tumor. Unlike flat (2D) cultures, spheroids allow cells to interact in multiple directions, form gradients of oxygen and nutrients, and exhibit invasion behaviors closer to what happens in actual tissue. This makes them more clinically relevant for testing drug effects on tumor spread.
What does Rho-GTPase signaling do in cancer cells?
Rho-GTPases (Ras homolog family guanosine triphosphatases) are a family of molecular switches that control the cell's internal skeleton, the cytoskeleton. In cancer, overactive Rho signaling helps tumor cells change shape, move, and invade surrounding tissues. By disrupting this pathway, mebendazole may block the physical machinery tumors need to spread.
Can mebendazole treat my meningioma?
No, mebendazole is not approved for meningioma treatment. This study is preclinical evidence from laboratory cell culture only. It is too early to know whether the same effects would occur in humans, at what dose, or whether it would be safe alongside standard treatments. Always consult a qualified oncologist or neurosurgeon for treatment decisions.
Meningioma is the most common brain tumor. When it becomes invasive (grade II), it is harder to remove and more likely to come back. In this laboratory study, researchers grew mini-tumors from actual patient cells in a gel-like material, then treated them with mebendazole an antiparasitic drug. The drug stopped the tumors from spreading in nearly 9 out of 10 samples. It appears to work by interfering with the cell's internal scaffolding, which is needed for movement. This is only lab evidence, not a human trial, and it does not mean mebendazole is a proven treatment for meningioma patients.
Shop Sanare Lab
Lab-tested products referenced in the research above. Links are provided for convenience — always review the label and consult a professional before use.
Lab-tested purity. 222 mg capsules, 90 count.
High-bioavailability curcumin, 120 capsules.
Disclaimer: Links are informational and for convenience. This site does not provide medical advice and does not endorse any specific vendor. Always verify product quality, labeling, and consult a licensed professional for health decisions.
References
- Dell et al. (2026). Mebendazole Attenuates Cellular Invasion in a 3D Culture Model of Meningioma by Disrupting Rho-GTPase-Mediated Microtubule Function. Oncology Research, 34(5), 21. PubMed
Medical Disclaimer
This article is for educational and informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Sanare Lab
Science-based health education team reviewing published research on repurposed drugs, integrative oncology, and evidence-based protocols.